Human Genome Sciences (HGSI), a commercially focused biopharmaceutical company, engages in the development of innovative drugs to patients with unmet medical needs. Its clinical development pipeline includes novel drugs to treat hepatitis C, lupus, inhalation anthrax and cancer.

HGSI is primarily focused on rapidly progressing the commercialization of its two lead drugs, BENLYSTA™ (belimumab) for lupus and ZALBIN™ (albinterferon alfa-2b, formerly Albuferon®) for hepatitis C. BENLYSTA has successfully met its primary endpoint in the first of two phase III trials in systemic lupus erythematosus, and results of the second BENLYSTA phase III trial are expected in November 2009. ZALBIN has now completed phase 3 development, and the submission of global marketing applications is expected in late fall 2009.

Through a strategic collaboration agreement with GlaxoSmithKline (GSK), HGSI has substantial financial rights to certain products in the GSK clinical pipeline, including darapladib that is in phase III development as a treatment for coronary heart disease; and Syncria (albiglutide), which is in phase III development as a treatment for type 2 diabetes. Additionally, it has a strategic commercial collaboration agreement with Novartis for the co-development and commercialization of Zalbin; and a strategic licensing and collaboration agreement with Aegera Therapeutics Inc. to develop and commercialize HGS1029 and other small-molecule inhibitors of IAP (inhibitor of apoptosis) proteins in oncology.

HGSI was founded in 1992 and is headquartered in Rockville, Maryland.

Source: Reuters.com, SEC Filings, FY ending December

Shares of HGSI were boosted Wednesday as analysts expressed bullish outlook on the stock. Citing its developing lupus drug Benlysta, Citi analyst Dr. Yaron Werber reaffirmed a “Buy” rating and boosted his price target to $30 from $17. In a note to investors, Weber said results from a mid-stage study on the drug candidate, along with management’s outlook, give him confidence that additional studies will also yield positive data.

Also, Goldman Sachs continues its coverage on the stock with a Buy rating and $24 price target. In addition to possible marketing approval of Benlysta, Zalbin and ABthrax, the firm is seeing HGSI as potential takeover target.

The Company is scheduled to discuss BENLYSTA and the phase III BLISS-52 trial results during an Analyst & Investor Meeting, which the Company will host at the 2009 American College of Rheumatology Annual Scientific Meeting. The HGSI Analyst & Investor meeting will begin at approximately 6:30 PM Eastern on Tuesday, October 20, 2009, and will be accessible by Web cast at www.hgsi.com.

Moving Average

HGSI has been relatively stable recently. This is evidenced by the width of its Bollinger Bands which are tighter than normal. Additionally, HGSI is trading near its upper Bollinger Band. This suggests that the stock price is high relative to its recent price action.

MACD

HGSI’s MACD is indicating a weak bearish signal. Although the indicator is above the critical level of 0, which implies that the underlying moving averages are bullish, the MACD has crossed below its 9-day moving average or signal line. This suggests that positive momentum has begun to slow.

Bollinger Bands

HGSI is trading within its Bollinger Bands. This is a normal condition and suggests that the stock is neither overbought nor oversold relative to the recent price action.

Source: http://www.scottrade.com

Abbott Laboratories (ABT) is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. It operates through four business segments: Pharmaceutical Products, which products include a line of adult and pediatric pharmaceuticals manufactured, marketed and sold worldwide; Nutritional Products, which offers a line of pediatric and adult nutritional products manufactured, marketed and sold worldwide; Diagnostic Products, which offers diagnostic systems and tests manufactured, marketed and sold worldwide to blood banks, hospitals, commercial laboratories; and Vascular Products, which product line includes coronary, endovascular and vessel closure devices manufactured, marketed and sold worldwide.

Founded in 1888, ABT employs 72,000 people and markets its products in more than 130 countries. The Company is based in Abbott Park, Illinois.

Source: Reuters.com, SEC Filings, FY ending December

ABT shares were up Wednesday as the Company reported a 16.5% earnings growth in the third quarter ended September 30, 2009. Its earnings of 92 cents per share topped estimates morning by two cents.

“Abbott is performing well, generating higher-than-expected earnings growth in the third quarter,” ABT chairman and CEO Miles D. White stated in the Company’s press release. “During the quarter, we announced several acquisitions that support our long-term growth strategy. These acquisitions add to our diverse mix of global businesses, with new technologies, established products and emerging market infrastructure that will help us deliver sustainable industry-leading growth. In particular, the acquisition of Solvay Pharmaceuticals will further diversify our global pharmaceuticals business.”

For the full year 2009, the Company looks to earn $3.70 to $3.72 per share, up from its previous guidance of $3.65 to $3.70 per share and the current consensus earnings estimate is $3.69 per share.

Moving Average

ABT is trading above its 13-day moving average. This is considered to be the sign of a bullish trend. There is added weight to this indication because the moving average is rising and suggests that there has been buying interest in this stock.

MACD

The MACD for ABT currently indicates a strong bullish signal for two reasons. First, the MACD is above the signal line, a 9-day moving average. Second, the MACD is above 0 which implies that the underlying moving averages are trending higher.

Bollinger Bands

ABT is trading near its upper Bollinger Band. This suggests that the stock price is high relative to its recent price action.

Source: http://www.scottrade.com

Report Disclaimer

DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice.

The information contained in our report should be viewed as commercial advertisement and is not intended to be investment advice. The report is not provided to any particular individual with a view toward their individual circumstances. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.

Our newsletter and website have been prepared for informational purposes only and are not intended to be used as a complete source of information on any particular company. An individual should never invest in the securities of any of the companies profiled based solely on information contained in our report. Individuals should assume that all information contained in the report about profiled companies is not trustworthy unless verified by their own independent research.

Any individual who chooses to invest in any securities should do so with caution. Investing in securities is speculative and carries a high degree of risk; you may lose some or all of the money that is invested. Always research your own investments and consult with a registered investment advisor or licensed stock broker before investing.

Information contained in our report will contain “forward looking statements” as defined under Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Subscribers are cautioned not to place undue reliance upon these forward looking statements. These forward looking statements are subject to a number of known and unknown risks and uncertainties outside of our control that could cause actual operations or results to differ materially from those anticipated. Factors that could affect performance include, but are not limited to, those factors that are discussed in each profiled company’s most recent reports or registration statements filed with the SEC. You should consider these factors in evaluating the forward looking statements included in the report and not place undue reliance upon such statements.

We are committed to providing factual information on the companies that are profiled. However, we do not provide any assurance as to the accuracy or completeness of the information provided, including information regarding a profiled company’s plans or ability to effect any planned or proposed actions. We have no first-hand knowledge of any profiled company’s operations and therefore cannot comment on their capabilities, intent, resources, nor experience and we make no attempt to do so. Statistical information, dollar amounts, and market size data was provided by the subject company and related sources which we believe to be reliable.

To the fullest extent of the law, we will not be liable to any person or entity for the quality, accuracy, completeness, reliability, or timeliness of the information provided in the report, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information we provide to any person or entity (including, but not limited to, lost profits, loss of opportunities, trading losses, and damages that may result from any inaccuracy or incompleteness of this information).

We encourage you to invest carefully and read investment information available at the websites of the SEC at http://www.sec.gov and FINRA at http://www.finra.org.